In Vitro Resistance Profile of the Hepatitis C Virus NS3 Protease Inhibitor BI 201335

被引:43
作者
Lagace, Lisette [1 ]
White, Peter W. [1 ]
Bousquet, Christiane [1 ]
Dansereau, Nathalie [1 ]
Do, Florence [1 ]
Llinas-Brunet, Montse [1 ]
Marquis, Martin [1 ]
Massariol, Marie-Josee [1 ]
Maurice, Roger [1 ]
Spickler, Catherine [1 ]
Thibeault, Diane [1 ]
Triki, Ibtissem [1 ]
Zhao, Songping [1 ]
Kukolj, George [1 ]
机构
[1] Boehringer Ingelheim Canada Ltd, Quebec City, PQ H7S 2G5, Canada
关键词
TELAPREVIR; SENSITIVITY; BOCEPREVIR; THERAPIES; VARIANTS; BINDING; VX-950; TMC435;
D O I
10.1128/AAC.05166-11
中图分类号
Q93 [微生物学];
学科分类号
071005 [微生物学];
摘要
The in vitro resistance profile of BI 201335 was evaluated through selection and characterization of variants in genotype 1a (GT 1a) and genotype 1b (GT 1b) replicons. NS3 R155K and D168V were the most frequently observed resistant variants. Phenotypic characterization of the mutants revealed shifts in sensitivity specific to BI 201335 that did not alter susceptibility to alpha interferon. In contrast to macrocyclic and covalent protease inhibitors, changes at V36, T54, F43, and Q80 did not confer resistance to BI 201335.
引用
收藏
页码:569 / 572
页数:4
相关论文
共 30 条
[1]
New direct-acting antivirals' combination for the treatment of chronic hepatitis C [J].
Asselah, Tarik ;
Marcellin, Patrick .
LIVER INTERNATIONAL, 2011, 31 :68-77
[2]
Susceptibility of Treatment-Naive Hepatitis C Virus (HCV) Clinical Isolates to HCV Protease Inhibitors [J].
Bae, Andrew ;
Sun, Siu-Chi ;
Qi, Xiaoping ;
Chen, Xiaowu ;
Ku, Karin ;
Worth, Angela ;
Wong, Kelly A. ;
Harris, Jeanette ;
Miller, Michael D. ;
Mo, Hongmei .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (12) :5288-5297
[3]
NONSTRUCTURAL PROTEIN-3 OF THE HEPATITIS-C VIRUS ENCODES A SERINE-TYPE PROTEINASE REQUIRED FOR CLEAVAGE AT THE NS3/4 AND NS4/5 JUNCTIONS [J].
BARTENSCHLAGER, R ;
AHLBORNLAAKE, L ;
MOUS, J ;
JACOBSEN, H .
JOURNAL OF VIROLOGY, 1993, 67 (07) :3835-3844
[4]
Induced-Fit Binding of the Macrocyclic Noncovalent Inhibitor TMC435 to its HCV NS3/NS4A Protease Target [J].
Cummings, Maxwell D. ;
Lindberg, Jimmy ;
Lin, Tse-I ;
de Kock, Herman ;
Lenz, Oliver ;
Lilja, Elisabet ;
Fellander, Sara ;
Baraznenok, Vera ;
Nystrom, Susanne ;
Nilsson, Magnus ;
Vrang, Lotta ;
Edlund, Michael ;
Rosenquist, Asa ;
Samuelsson, Bertil ;
Raboisson, Pierre ;
Simmen, Kenneth .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2010, 49 (09) :1652-1655
[5]
Challenges and successes in developing new therapies for hepatitis C [J].
De Francesco, R ;
Migliaccio, G .
NATURE, 2005, 436 (7053) :953-960
[6]
The role of triple therapy in HCV genotype 1-experienced patients [J].
Fried, Michael W. .
LIVER INTERNATIONAL, 2011, 31 :58-61
[7]
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection [J].
Jacobson, Ira M. ;
McHutchison, John G. ;
Dusheiko, Geoffrey ;
Di Bisceglie, Adrian M. ;
Reddy, K. Rajender ;
Bzowej, Natalie H. ;
Marcellin, Patrick ;
Muir, Andrew J. ;
Ferenci, Peter ;
Flisiak, Robert ;
George, Jacob ;
Rizzetto, Mario ;
Shouval, Daniel ;
Sola, Ricard ;
Terg, Ruben A. ;
Yoshida, Eric M. ;
Adda, Nathalie ;
Bengtsson, Leif ;
Sankoh, Abdul J. ;
Kieffer, Tara L. ;
George, Shelley ;
Kauffman, Robert S. ;
Zeuzem, Stefan .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (25) :2405-2416
[8]
Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase [J].
Kukolj, G ;
McGibbon, GA ;
McKercher, G ;
Marquis, M ;
Lefèbvre, S ;
Thauvette, L ;
Gauthier, J ;
Goulet, S ;
Poupart, MA ;
Beaulieu, PL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (47) :39260-39267
[9]
BI 201335, A POTENT HCV NS3 PROTEASE INHIBITOR, IN TREATMENT-NAIVE AND -EXPERIENCED CHRONIC HCV GENOTYPE-1 INFECTION: GENOTYPIC AND PHENOTYPIC ANALYSIS OF THE NS3 PROTEASE DOMAIN [J].
Kukolj, G. ;
Benhamou, Y. ;
Manns, M. P. ;
Bourliere, M. ;
Pol, S. ;
Schuchmann, M. ;
Cartier, M. ;
Huang, D. ;
Lagace, L. ;
Steinmann, G. ;
Stern, J. O. .
JOURNAL OF HEPATOLOGY, 2009, 50 :S347-S347
[10]
Lagace L., 2006, FRAMING KNOWLEDGE VI, P263